Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Follicular 25Lymphoma, Mantle-Cell 23Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell 16Lymphoma, B-Cell, Marginal Zone 13Neoplasms 8Recurrence 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Burkitt Lymphoma 5Neoplasm, Residual 3Lymphoproliferative Disorders 3Leukemia, Hairy Cell 3Hematologic Diseases 3Myelodysplastic Syndromes 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Sarcoma, Myeloid 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuritis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myeloid Diseases 1

Interventions

Rituximab 1Lenalidomide 1CT-P10 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Composite Lymphoma × Rituximab × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡